JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

NCT07690787 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Recurrent/ Metastatic NPC

Interventions

DRUG: JS207
DRUG: Paclitaxel
DRUG: Capecitabine

Sponsor

Chinese University of Hong Kong